173 related articles for article (PubMed ID: 36810257)
1. The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy.
Vendetti FP; Pandya P; Clump DA; Schamus-Haynes S; Tavakoli M; diMayorca M; Islam NM; Chang J; Delgoffe GM; Beumer JH; Bakkenist CJ
JCI Insight; 2023 Feb; 8(4):. PubMed ID: 36810257
[TBL] [Abstract][Full Text] [Related]
2. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
3. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.
Vendetti FP; Karukonda P; Clump DA; Teo T; Lalonde R; Nugent K; Ballew M; Kiesel BF; Beumer JH; Sarkar SN; Conrads TP; O'Connor MJ; Ferris RL; Tran PT; Delgoffe GM; Bakkenist CJ
J Clin Invest; 2018 Aug; 128(9):3926-3940. PubMed ID: 29952768
[TBL] [Abstract][Full Text] [Related]
4. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
Liu C; Wang X; Qin W; Tu J; Li C; Zhao W; Ma L; Liu B; Qiu H; Yuan X
Cancer Commun (Lond); 2023 Apr; 43(4):435-454. PubMed ID: 36855844
[TBL] [Abstract][Full Text] [Related]
5. ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment.
Dillon MT; Bergerhoff KF; Pedersen M; Whittock H; Crespo-Rodriguez E; Patin EC; Pearson A; Smith HG; Paget JTE; Patel RR; Foo S; Bozhanova G; Ragulan C; Fontana E; Desai K; Wilkins AC; Sadanandam A; Melcher A; McLaughlin M; Harrington KJ
Clin Cancer Res; 2019 Jun; 25(11):3392-3403. PubMed ID: 30770349
[TBL] [Abstract][Full Text] [Related]
6. Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment.
Ao W; Kim HI; Tommarello D; Conrads KA; Hood BL; Litzi T; Abulez T; Teng PN; Dalgard CL; Zhang X; Wilkerson MD; Darcy KM; Tarney CM; Phippen NT; Bakkenist CJ; Maxwell GL; Conrads TP; Risinger JI; Bateman NW
Gynecol Oncol; 2023 Oct; 177():60-71. PubMed ID: 37639904
[TBL] [Abstract][Full Text] [Related]
7. ATR inhibition induces synthetic lethality in mismatch repair-deficient cells and augments immunotherapy.
Wang M; Ran X; Leung W; Kawale A; Saxena S; Ouyang J; Patel PS; Dong Y; Yin T; Shu J; Manguso RT; Lan L; Wang XF; Lawrence MS; Zou L
Genes Dev; 2023 Oct; 37(19-20):929-943. PubMed ID: 37932012
[TBL] [Abstract][Full Text] [Related]
8. Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-α/β expression.
Sugitani N; Vendetti FP; Cipriano AJ; Pandya P; Deppas JJ; Moiseeva TN; Schamus-Haynes S; Wang Y; Palmer D; Osmanbeyoglu HU; Bostwick A; Snyder NW; Gong YN; Aird KM; Delgoffe GM; Beumer JH; Bakkenist CJ
Cell Rep; 2022 Sep; 40(12):111371. PubMed ID: 36130512
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice.
Kiesel BF; Guo J; Parise RA; Venkataramanan R; Clump DA; Bakkenist CJ; Beumer JH
Cancer Chemother Pharmacol; 2022 Feb; 89(2):231-242. PubMed ID: 35066692
[TBL] [Abstract][Full Text] [Related]
10. Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.
Marciscano AE; Ghasemzadeh A; Nirschl TR; Theodros D; Kochel CM; Francica BJ; Muroyama Y; Anders RA; Sharabi AB; Velarde E; Mao W; Chaudhary KR; Chaimowitz MG; Wong J; Selby MJ; Thudium KB; Korman AJ; Ulmert D; Thorek DLJ; DeWeese TL; Drake CG
Clin Cancer Res; 2018 Oct; 24(20):5058-5071. PubMed ID: 29898992
[No Abstract] [Full Text] [Related]
11. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
[TBL] [Abstract][Full Text] [Related]
12. An orally available cancer drug AZD6738 prevents type 1 diabetes.
Sugitani N; Mason HR; Campfield BT; Piganelli JD
Front Immunol; 2023; 14():1290058. PubMed ID: 38164129
[TBL] [Abstract][Full Text] [Related]
13. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer.
Hsieh RC; Krishnan S; Wu RC; Boda AR; Liu A; Winkler M; Hsu WH; Lin SH; Hung MC; Chan LC; Bhanu KR; Srinivasamani A; De Azevedo RA; Chou YC; DePinho RA; Gubin M; Vilar E; Chen CH; Slay R; Jayaprakash P; Hegde SM; Hartley G; Lea ST; Prasad R; Morrow B; Couillault CA; Steiner M; Wang CC; Venkatesulu BP; Taniguchi C; Kim YSB; Chen J; Rudqvist NP; Curran MA
Sci Immunol; 2022 Jun; 7(72):eabl9330. PubMed ID: 35687697
[TBL] [Abstract][Full Text] [Related]
14. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
15. Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy.
Buchwald ZS; Nasti TH; Lee J; Eberhardt CS; Wieland A; Im SJ; Lawson D; Curran W; Ahmed R; Khan MK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028691
[TBL] [Abstract][Full Text] [Related]
16. Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression.
Pierini S; Mishra A; Perales-Linares R; Uribe-Herranz M; Beghi S; Giglio A; Pustylnikov S; Costabile F; Rafail S; Amici A; Facciponte JG; Koumenis C; Facciabene A
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563772
[TBL] [Abstract][Full Text] [Related]
17. ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Wilson Z; Odedra R; Wallez Y; Wijnhoven PWG; Hughes AM; Gerrard J; Jones GN; Bargh-Dawson H; Brown E; Young LA; O'Connor MJ; Lau A
Cancer Res; 2022 Mar; 82(6):1140-1152. PubMed ID: 35078817
[TBL] [Abstract][Full Text] [Related]
18. Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8
Rolig AS; Rose DC; McGee GH; Rubas W; Kivimäe S; Redmond WL
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35444059
[TBL] [Abstract][Full Text] [Related]
19. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
[TBL] [Abstract][Full Text] [Related]
20. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]